期刊文献+

2012年美国FDA批准药物简介 被引量:4

Overviews and analysis to the U.S.FDA′s new approvals in 2012
在线阅读 下载PDF
导出
摘要 2012年美国食品药品监督管理局(FDA)批准上市新药34种,其中首次批准上市新分子实体23个,新生物制品11个。本文根据FDA批准新药说明书首页处方资料要点,简要介绍新药概况、作用机制、适应证、剂量和用法、黑框警告、禁忌证、不良反应、药物相互作用及特殊人群中使用要点等。并讨论了2012批准新药在药物开发、研究和审评中的首次事件。 In 2012,the U.S.Food and Drug Administration(FDA) approved 34 new drugs,including 23 new molecular entities and 11 new biological products.According to the prescription information for professionals,this article briefly describes the description,mechanism of action,the box warning,indications and usage,dosage and administration,dosage form and strength,contraindications,warning and precautions,adverse reactions,drug interaction and use of these new drugs in special population.In addition,the "first events" in the history of new drug research,development and approval are also discussed.
作者 汤仲明
出处 《国际药学研究杂志》 CAS CSCD 2013年第1期111-123,共13页 Journal of International Pharmaceutical Research
关键词 新药批准 美国FDA 新分子实体 新生物制品 化学结构 作用机制 适应证 不良反应 new drug approval the U.S.FDA new molecular entity new biological product chemical structure mechanism indications adverse reactions
  • 相关文献

参考文献10

  • 1Scher HI,Fizazi K,Saad F,et al.Increased survival with enz-alutamide in prostate cancer after chemotherapy[].The New England Journal of Medicine.2012
  • 2Colman E,Golden J,Roberts M,et al.The FDA’’s assessment of two drugs for chronic weight management[].The New England Journal of Medicine.2012
  • 3Besarab A,Zeig SN,Martin ER,et al.An open-label,sequen-tial,dose-finding study of peginesatide for the maintenance treat-ment of anemia in chronic hemodialysis patients[].BMC Neph-rol.2012
  • 4Flume PA,Liou TG,Borowitz DS,et al.Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation[].Chest.2012
  • 5Besag FM,Patsalos PN.New developments in the treatment of partial-onset epilepsy[].Neuropsychiat Dis Treat.2012
  • 6Demetri GD,Reichardt P,Kang YK,et al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID):an international,mul-ticentre,randomised,placebo-controlled,phase3trial[].The Lancet.2012
  • 7O’’Connor P,Wolinsky JS,Confavreux C,et al.Randomized tri-al of oral teriflunomide for relapsing multiple sclerosis[].The New England Journal of Medicine.2011
  • 8Sekulic A,Migden MR,Oro AE,Dirix L,et al.Efficacy and safety of vismodegib in advanced basal-cell carcinoma[].The New England Journal of Medicine.2012
  • 9Lebwohl M,Swanson N,Anderson LL,el al.Ingenol mebutate gel for actinic keratosis[].The New England Journal of Medicine.2012
  • 10Bukowski RM.Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma[].Front Oncol.2012

同被引文献66

  • 1尚兰琴,魏雪涛,杨晓华,将建军,郝卫东.不同剂型膦甲酸钠针剂的肾脏毒性[J].毒理学杂志,2006,20(2):131-132. 被引量:3
  • 2WHO药品不良反应术语集 累及的系统-器官代码检索目录[J].中国药物警戒,2007,4(1):58-64. 被引量:35
  • 3钟福华.艾滋病在中国的流行特点 原因与防治对策[J].预防医学情报杂志,2007,23(2):200-204. 被引量:31
  • 4陈康庆,梅丽琴,林塘焕,等.多肽药物研究进展[C].中国药学大会暨第十届中国药师周论文集.2010.
  • 5Sun J, Chen X, Deng C, et al. Direct formation of giant vesicles from synthetic polypeptides[J]. Langmuir, 2007, 23(16): 8308-8315.
  • 6Nestor J J,Jr. The medicinal chemistry of peptides[J]. Curr Med Chern, 2009,16 (33): 4399-4418.
  • 7Sistiabudi R, Ivanisevic A. Patterning of polypeptides on a co\lagen?terminated tissue surface[J]. J Phys Chern Solid, 2007, 111(31): 11676- 11681.
  • 8Agut W, Taton D, Lecornmandoux S. A versatile synthetic approach to polypeptide based rod-coil block copolymers by click chemistry[J]. Macromolecules, 2007, 40 (16): 5653-5661.
  • 9休厄德N,贾库布克HD.肽:化学与生物学[M].刘克良,何军林,等译.北京:科学出版社,2005.
  • 10Delmar M, Taffet S M, Wanda C, et al. Compounds acting as peptide gap junction modulators, and uses thereof: US, 13/377773[P). 2012-10- 18.

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部